IKT
NASDAQ · Biotechnology
Inhibikase Therapeutics Inc
$2.03
+0.10 (+5.18%)
Open$1.93
Previous Close$1.93
Day High$2.05
Day Low$1.92
52W High$2.26
52W Low$1.33
Volume—
Avg Volume665.3K
Market Cap252.18M
P/E Ratio—
EPS$-1.15
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+1,279.8% upside
Current
$2.03
$2.03
Target
$28.01
$28.01
$19.41
$28.01 avg
$39.32
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 78.22M | 74.95M | 61.90M |
| Net Income | 4.38M | 5.16M | 3.75M |
| Profit Margin | 5.6% | 6.9% | 6.1% |
| EBITDA | 7.32M | 7.08M | 6.90M |
| Free Cash Flow | 4.21M | 5.04M | 4.89M |
| Rev Growth | +8.7% | +15.3% | -5.1% |
| Debt/Equity | 0.35 | 0.45 | 0.33 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |